A Yen for Funding and Partnering - the value of developing relationships with Japan Pharma
Forging relationships with Japanese pharmaceutical companies can provide attractive routes of funding, with this event focusing on the pros and cons of the corporate venture capital route and strategic alliances and partnering.
Like venture capital firms, corporate VCs may differ in their goals and strategies. This is an opportunity to hear how two Japanese corporate VC funds operate, what their investments are and why corporate venture capital represents an attractive source of funds.
Both early stage and mature venture capital companies are increasingly relying on strategic alliances and partnering as a route to financing clinical and corporate development without loosing the benefit from commercialization of their products. Although partnering can be an attractive option, finding the right partner and managing the relationship are essential. We will hear from two companies about their experiences of working with major Japanese pharmaceutical companies. This event will be moderated by Stuart Wren who worked in Japan for 10 years for GSK and its heritage companies.
Presenters:
Yoshitaka Yoneyama, President & CEO, Astellas Venture Management LLC
Graeme Martin, President & CEO, Takeda Research Investment, Inc.
Chris Dammann, Vice President, Business Development, Affymax Inc.
Natalie Holles, Senior Director, Business Development, Kai Pharmaceuticals, Inc.
